克隆氏症治疗市场－全球产业规模、份额、趋势、机会及预测（依药物类型、应用、通路、地区及竞争格局划分，2021-2031年）

全球克隆氏症治疗市场预计将从 2025 年的 120.4 亿美元成长到 2031 年的 153.1 亿美元，复合年增长率为 4.09%。

该市场涵盖多种药物治疗方法，包括免疫调节剂、抗生素和生物製药，旨在诱导和维持慢性发炎性疾病患者的病情缓解。市场成长的主要驱动因素是已开发国家该疾病盛行率的不断上升以及新疗法的持续核准。根据克隆氏症和结肠炎基金会2024年的数据，约有100,429名20岁以下的美国人患有发炎性肠道疾病，其中克隆氏症在该年龄层的盛行率显着高于溃疡性大肠炎。这凸显了持续医疗管理的日益增长的需求。

然而，市场面临严峻的挑战，因为先进生物疗法的高成本往往会阻碍患者获得治疗和报销。严格的监管要求以及持续治疗方案带来的沉重经济负担，可能会延缓有效药物的推广，尤其是在医疗预算有限的地区。因此，这些经济压力可能会限制高端治疗方法的市场渗透率，迫使医疗服务提供者依赖价格较低的传统疗法。

市场驱动因素

市场扩张的主要驱动力是克隆氏症在全球盛行率和发病率的持续上升。这种日益加重的疾病负担不再局限于已开发国家，而且由于环境因素和生活方式的改变，在新兴工业化地区也显着加速成长。不断扩大的患者群体需要长期持续的医疗管理，从而确保了对治疗性介入的持续需求。欧洲克隆氏症和溃疡性大肠炎协会联盟 (EFCCA) 在其 2025 年世界发炎性肠道疾病日报告中指出，全球目前有超过 1,000 万人患有发炎性肠道疾病，这凸显了需要有效治疗的患者群体规模之庞大。

同时，先进生物製药的快速普及正在重塑市场格局。与传统治疗方法相比，先进生物製剂具有更优的疗效和安全性，新药类别也核准。医疗机构正在加速患者向下一代治疗方法（例如白细胞介素抑制剂）的过渡，以实现更深层的缓解，从而推动创新疗法的显着收入成长。财务数据也印证了这个趋势。艾伯维公司2025年1月发布的报告预测，其先进疗法Skyrizi在2024年的全球净销售额将达到117亿美元。同样，强生公司报告称，其成熟的生物製药Stelara在2024年的销售额将达到104亿美元，这表明儘管面临来自新参与企业和生物类似药日益增长的压力，生物製药製剂领域的投资规模依然巨大。

市场挑战

先进生物疗法的高成本是全球克隆氏症治疗市场扩张的一大障碍。儘管这些药物疗效显着，但其定价结构给患者造成了严重的用药障碍，并加重了医疗预算的负担。保险公司通常会实施严格的报销通讯协定，例如阶梯疗法，要求患者在核准更昂贵的治疗之前，必须先尝试其他费用较低的替代疗法，且疗效不佳。这种经济负担会降低患者的治疗顺从性，延误最佳治疗方案的启动，并直接降低先进疗法的获利能力。

患者群体面临的经济负担是可以量化的，而且十分沉重。据克隆氏症和结肠炎基金会称，到2024年，超过40%的发炎性肠道疾病患者将不得不做出巨大的经济牺牲来支付医疗费用。此外，63%服用处方药的患者表示，他们面临特定的经济障碍，导致无法接受治疗。无力负担处方治疗方案的费用限制了高价值生物製药的市场渗透率，迫使市场依赖价格较低的学名药和生物相似药。

市场趋势

经济实惠的生物相似药的加速普及正在从根本上重塑全球克隆氏症治疗市场，为高价的生物製药提供了更经济实惠的替代方案。随着关键单株抗体的专利保护期即将到期，监管机构正在加快核准生物相似药候选药物，从而缓解目前限制患者获得生物疗法的经济障碍。这些低成本选择的涌入迫使支付方调整药品目录结构，提高了对成本敏感地区的市场渗透率，并挑战了品牌药的主导地位。根据 Askera Health 于 2025 年 1 月发布的一份报告，仅在 2024 年，FDA核准了六种不同的重磅药物Stelara的生物相似药，这标誌着处方量将显着转向这些更经济的治疗方案。

同时，口服小分子疗法的兴起正在重新定义治疗模式，它将高效性与便利的口服给药方式结合。与需要皮下或静脉注射的生物製药不同，先进的Janus激酶（JAK）抑制剂和S1P受体调变器提供了非侵入性治疗选择，显着提高了患者的生活方式柔软性和依从性。这项转变正在迅速发展，临床数据显示，这些口服疗法可以达到与注射型生物製药相当的缓解率。为了佐证这项需求，艾伯维公司于2025年1月公布，其口服JAK抑制剂Rinvoq在2024年全年的全球净销售额达到60亿美元，反映了这种便捷、先进的治疗机制的强劲增长。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球克隆氏症治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类型（抗生素、氨基水杨酸盐、皮质类固醇、免疫调节剂、其他）
  • 根据适应症（神经病变疼痛、纤维肌痛、慢性下背痛、关节炎疼痛、偏头痛、术后疼痛、癌症疼痛等）
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美克隆氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲克隆氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区克隆氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲克隆氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲克隆氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球克隆氏症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Eli Lilly and Company
• AbbVie Inc.
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Celgene Corporation
• Novartis AG
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Mylan NV
• Amgen Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Crohn's Disease Treatment Market is projected to expand from USD 12.04 Billion in 2025 to USD 15.31 Billion by 2031, reflecting a compound annual growth rate of 4.09%. This market comprises a range of pharmaceutical interventions, such as immunomodulators, antibiotics, and biologic therapies, all aimed at inducing and maintaining remission in patients suffering from this chronic inflammatory condition. Growth is primarily driven by the rising prevalence of the disease in industrialized nations and the continued approval of new therapeutic agents. Data from the Crohn's & Colitis Foundation in 2024 indicates that approximately 100,429 American youths under the age of 20 are living with Inflammatory Bowel Disease, with Crohn's disease notably more prevalent than ulcerative colitis in this demographic, highlighting the expanding need for ongoing medical management.

However, the market faces significant obstacles due to the high costs associated with advanced biologic therapies, which frequently create barriers to patient access and reimbursement. Strict regulatory requirements and the substantial financial burden of continuous treatment plans can delay the adoption of effective medications, particularly in regions with limited healthcare budgets. Consequently, these economic pressures may restrict the market penetration of premium therapeutic options, compelling healthcare providers to rely on older and less expensive alternatives.

Market Driver

The primary catalyst for market expansion is the relentlessly increasing global prevalence and incidence of Crohn's disease. This growing disease burden is no longer limited to Western nations but is visibly accelerating in newly industrializing regions, driven by shifting environmental factors and lifestyle changes. The expansion of the patient pool necessitates long-term, continuous medical management, thereby ensuring sustained demand for therapeutic interventions. Underscoring the immense scale of the population requiring effective treatment, the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) noted in their 'World IBD Day Report 2025' that there are currently over 10 million people worldwide living with inflammatory bowel diseases.

Simultaneously, the market is being reshaped by the rapid adoption of advanced biologics and the approval of novel drug classes that offer superior efficacy and safety profiles compared to legacy therapies. Healthcare providers are increasingly transitioning patients to next-generation mechanisms, such as interleukin inhibitors, to achieve deeper remission, which drives significant revenue growth for innovative formulations. Financial data substantiates this trend; according to AbbVie's January 2025 report, global net revenues for the advanced therapy Skyrizi reached $11.7 billion for the full year 2024. Similarly, Johnson & Johnson reported that the established biologic Stelara generated $10.4 billion in sales during 2024, illustrating the massive scale of investment in biologic care despite mounting pressure from newer entrants and biosimilars.

Market Challenge

The high cost of advanced biologic therapies constitutes a substantial barrier impeding the expansion of the Global Crohn's Disease Treatment Market. While these drugs offer efficacy, their pricing structures create severe accessibility issues for patients and strain healthcare budgets. Insurance providers frequently implement strict reimbursement protocols, such as step therapy, compelling patients to fail on cheaper alternatives before approving premium treatments. This financial toxicity discourages adherence and delays the initiation of optimal care, directly reducing the revenue potential for advanced therapeutic agents.

The economic strain on the patient population is quantifiable and severe. According to the Crohn's & Colitis Foundation, in 2024, more than 40% of inflammatory bowel disease patients made significant financial sacrifices to afford their healthcare. Furthermore, 63% of patients prescribed medication reported facing specific financial barriers that prevented them from obtaining their treatment. This inability to afford prescribed regimens limits the market penetration of high-value biologics and forces a market reliance on lower-cost generics or biosimilars.

Market Trends

The accelerating adoption of cost-effective biosimilars is fundamentally restructuring the Global Crohn's Disease Treatment Market by introducing affordable alternatives to high-priced legacy biologics. As patent exclusivities for major monoclonal antibodies expire, regulatory bodies are expediting the approval of biosimilar candidates, which mitigates the financial barriers currently restricting patient access to biologic therapy. This influx of lower-cost options is compelling payers to adjust formulary structures, thereby driving market penetration in cost-sensitive regions and challenging the dominance of originator drugs. According to an AscellaHealth report from January 2025, the FDA approved six distinct biosimilars for the blockbuster drug Stelara in 2024 alone, signaling a massive shift in prescription volume toward these economical therapeutic options.

Concurrently, the shift toward oral small molecule therapeutics is redefining treatment paradigms by offering potent efficacy combined with the convenience of pill-based administration. Unlike traditional biologics that require subcutaneous or intravenous delivery, advanced Janus kinase (JAK) inhibitors and S1P receptor modulators provide patients with a non-invasive option that significantly improves lifestyle flexibility and adherence. This transition is rapidly gaining momentum as clinical data demonstrates that these oral therapies can achieve remission rates comparable to injectable biologics. Highlighting this demand, AbbVie reported in January 2025 that global net revenues for the oral JAK inhibitor Rinvoq reached $6.0 billion for the full year 2024, reflecting robust growth for convenient, advanced therapeutic mechanisms.

Key Market Players

• Eli Lilly and Company
• AbbVie Inc.
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Celgene Corporation
• Novartis AG
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Mylan N.V.
• Amgen Inc

Report Scope

In this report, the Global Crohn's Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Crohn's Disease Treatment Market, By Drug Type

• Antibiotics
• Amino Salicylates
• Corticosteroids
• Immunomodulator
• Other

Crohn's Disease Treatment Market, By Application

• Neuropathic Pain
• Fibromyalgia
• Chronic Back Pain
• Arthritic Pain
• Migraine Post-Operative Pain
• Cancer Pain
• Other

Crohn's Disease Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Crohn's Disease Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Crohn's Disease Treatment Market.

Available Customizations:

Global Crohn's Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Crohn's Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulator, Other)
  • 5.2.2. By Application (Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Crohn's Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Crohn's Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Crohn's Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Crohn's Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Crohn's Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Crohn's Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Crohn's Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Crohn's Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Crohn's Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Crohn's Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Crohn's Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Crohn's Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Crohn's Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Crohn's Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Crohn's Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Crohn's Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Crohn's Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Crohn's Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Crohn's Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Crohn's Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America Crohn's Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Crohn's Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Crohn's Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Crohn's Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Crohn's Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Eli Lilly and Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AbbVie Inc.
• 15.3. AstraZeneca plc
• 15.4. Boehringer Ingelheim GmbH
• 15.5. Celgene Corporation
• 15.6. Novartis AG
• 15.7. Sanofi SA
• 15.8. Takeda Pharmaceutical Company Limited
• 15.9. Mylan N.V.
• 15.10. Amgen Inc

16. Strategic Recommendations

17. About Us & Disclaimer